PremiumThe FlyTrump urges drugmakers to accept lower prices on prescriptions, Bloomberg says Sanofi treatment of multiple myeloma granted FDA orphan status Vaxcyte appoints Brandicourt to board of directors PremiumRatingsSanofi’s Undervalued Stock and Promising Growth Justify Buy Rating Sanofi’s Q1 2025 Earnings: Strong Growth Amid Challenges Sanofi Reports Strong Q1 2025 Performance PremiumThe FlySanofi expects FY25 business EPS growth at LDD percentage at CER Innate Pharma announces EUR 15M capital increase from Sanofi Sanofi’s Strong Financial Performance and Promising R&D Pipeline Justify Buy Rating